Annexin Pharmaceuticals AB (publ) (ANNX.ST)
SEK 0.28
(0.35%)
SEK 0.28
(0.35%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -44.05 Million SEK | -8.17% |
| 2022 | -40.72 Million SEK | 23.23% |
| 2021 | -53.05 Million SEK | -18.57% |
| 2020 | -44.74 Million SEK | -57.58% |
| 2019 | -28.39 Million SEK | 1.57% |
| 2018 | -28.84 Million SEK | 6.73% |
| 2017 | -30.92 Million SEK | -214.62% |
| 2016 | -9.83 Million SEK | -95.47% |
| 2015 | -5.02 Million SEK | -262.59% |
| 2014 | -1.38 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -12.45 Million SEK | 14.36% |
| 2024 Q2 | -14.51 Million SEK | -16.49% |
| 2024 Q3 | -10.92 Million SEK | 24.71% |
| 2023 Q3 | -10.83 Million SEK | -26.46% |
| 2023 Q2 | -8.56 Million SEK | 15.18% |
| 2023 FY | -44.05 Million SEK | -8.17% |
| 2023 Q1 | -10.1 Million SEK | 0.17% |
| 2023 Q4 | -14.54 Million SEK | -34.26% |
| 2022 Q2 | -11.51 Million SEK | -21.88% |
| 2022 Q1 | -9.44 Million SEK | 40.58% |
| 2022 Q4 | -10.12 Million SEK | -4.92% |
| 2022 Q3 | -9.64 Million SEK | 16.23% |
| 2022 FY | -40.72 Million SEK | 23.23% |
| 2021 Q1 | -19.05 Million SEK | -16.39% |
| 2021 Q2 | -9 Million SEK | 52.74% |
| 2021 Q4 | -15.9 Million SEK | -94.45% |
| 2021 FY | -53.05 Million SEK | -18.57% |
| 2021 Q3 | -8.17 Million SEK | 9.22% |
| 2020 Q3 | -8.19 Million SEK | 29.28% |
| 2020 Q4 | -16.37 Million SEK | -99.71% |
| 2020 Q1 | -8.07 Million SEK | 22.04% |
| 2020 FY | -44.74 Million SEK | -57.58% |
| 2020 Q2 | -11.59 Million SEK | -43.58% |
| 2019 Q3 | -6.46 Million SEK | -8.0% |
| 2019 FY | -28.39 Million SEK | 1.57% |
| 2019 Q4 | -10.35 Million SEK | -60.09% |
| 2019 Q2 | -5.99 Million SEK | -8.01% |
| 2019 Q1 | -5.54 Million SEK | 23.73% |
| 2018 Q2 | -7.75 Million SEK | 13.69% |
| 2018 Q1 | -8.98 Million SEK | 5.91% |
| 2018 Q3 | -4.83 Million SEK | 37.71% |
| 2018 Q4 | -7.27 Million SEK | -50.5% |
| 2018 FY | -28.84 Million SEK | 6.73% |
| 2017 Q1 | -7.44 Million SEK | -109.87% |
| 2017 FY | -30.92 Million SEK | -214.62% |
| 2017 Q2 | -10.14 Million SEK | -36.34% |
| 2017 Q3 | -3.78 Million SEK | 62.73% |
| 2017 Q4 | -9.55 Million SEK | -152.47% |
| 2016 Q2 | -884 Thousand SEK | -41.44% |
| 2016 Q1 | -625 Thousand SEK | 0.0% |
| 2016 FY | -9.83 Million SEK | -95.47% |
| 2016 Q4 | -3.54 Million SEK | 25.7% |
| 2016 Q3 | -4.77 Million SEK | -440.05% |
| 2015 FY | -5.02 Million SEK | -262.59% |
| 2014 FY | -1.38 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -12.82 Million SEK | -243.421% |
| BioArctic AB (publ) | 229.24 Million SEK | 119.217% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -146.153% |
| CombiGene AB (publ) | -35.66 Million SEK | -23.52% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 70.988% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -168.655% |
| OncoZenge AB (publ) | -15.9 Million SEK | -177.034% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 82.278% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 90.55% |
| Mendus AB (publ) | -101.61 Million SEK | 56.648% |
| LIDDS AB (publ) | -40.2 Million SEK | -9.571% |
| Lipum AB (publ) | -37.17 Million SEK | -18.495% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 462.018% |
| Simris Alg AB (publ) | -37.3 Million SEK | -18.091% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -4.336% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -85.592% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 88.651% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 75.48% |
| Ziccum AB (publ) | -21.41 Million SEK | -105.744% |
| AcouSort AB (publ) | -17.08 Million SEK | -157.792% |
| Active Biotech AB (publ) | -45.8 Million SEK | 3.812% |
| Alzinova AB (publ) | -16.48 Million SEK | -167.318% |
| Amniotics AB (publ) | -30.87 Million SEK | -42.708% |
| Camurus AB (publ) | 431.44 Million SEK | 110.211% |
| Cantargia AB (publ) | -280.02 Million SEK | 84.268% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -108.876% |
| Genovis AB (publ.) | 61.5 Million SEK | 171.633% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 61.125% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -18.837% |
| Intervacc AB (publ) | -102.85 Million SEK | 57.168% |
| Kancera AB (publ) | -64.88 Million SEK | 32.109% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 917.935% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -263.242% |
| NextCell Pharma AB | -41.95 Million SEK | -4.991% |
| Saniona AB (publ) | -95.81 Million SEK | 54.019% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 85.832% |
| Xintela AB (publ) | -54.08 Million SEK | 18.544% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -9957.991% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -166.622% |
| Corline Biomedical AB | -1.8 Million SEK | -2335.268% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 75.228% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 22.469% |
| Aptahem AB (publ) | -11.11 Million SEK | -296.423% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 64.204% |
| Fluicell AB (publ) | -26.55 Million SEK | -65.903% |
| Biovica International AB (publ) | -124.82 Million SEK | 64.707% |
| Abliva AB (publ) | -95.5 Million SEK | 53.875% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 86.524% |
| 2cureX AB (publ) | -32.51 Million SEK | -35.476% |
| I-Tech AB | 20.2 Million SEK | 318.057% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 94.703% |
| Cyxone AB (publ) | -22.98 Million SEK | -91.631% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 51.801% |
| Biosergen AB | -27.03 Million SEK | -62.94% |
| Nanologica AB (publ) | -75.15 Million SEK | 41.384% |
| SynAct Pharma AB | -215.81 Million SEK | 79.587% |
| BioInvent International AB (publ) | -330.3 Million SEK | 86.663% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 82.316% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -343.645% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 59.69% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -277.239% |